New immune cell therapy targets Hard-to-Treat leukemia
NCT ID NCT07556757
First seen May 04, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment called CD19 t-haNK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after prior therapy. The treatment uses specially designed immune cells to attack cancer cells. Up to 10 participants will receive the therapy to check its safety and see if it helps control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Alberts Cellular Therapy
RECRUITINGPretoria, 0044, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dr Jackie Thomson Inc
RECRUITINGJohannesburg, 2193, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.